文献速递心力衰竭与心肌病

达格列净对射血分数保留心衰的心脏与代谢效应:CAMEO-DAPA试验

Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
PubMed 文献 · Circulation · 2023-08-03

CAMEO-DAPA是一项单中心、双盲、随机、安慰剂对照试验,纳入38例有运动时肺毛细血管楔压升高的HFpEF患者,评估达格列净10 mg每日一次治疗24周对静息和运动血流动力学的影响。结果显示达格列净降低静息和运动时PCWP,并降低体重和血浆容量,对红细胞容量无显著影响。

要点

  • 达格列净降低HFpEF患者静息和运动时肺毛细血管楔压。
  • 达格列净降低体重和血浆容量,对红细胞容量无显著影响。
  • 达格列净降低20W运动时动脉乳酸,氧耗无显著差异。

核心结论

  • 在HFpEF患者中,达格列净降低静息和运动时PCWP,并改善血浆容量和体重。

研究设计与样本

  • 单中心、双盲、随机、安慰剂对照试验,纳入38例NYHA II或III级、EF≥50%且运动时PCWP升高的HFpEF患者,37例完成试验。

主要发现

  • 达格列净组静息PCWP估计治疗差异为-3.5 mm Hg(95% CI,-6.6至-0.4;P=0.029)。
  • 达格列净组最大运动PCWP估计治疗差异为-5.7 mm Hg(95% CI,-10.8至-0.7;P=0.027)。
  • 达格列净组体重估计治疗差异为-3.5 kg(95% CI,-5.9至-1.1;P=0.006)。
  • 达格列净组血浆容量估计治疗差异为-285 mL(95% CI,-510至-60;P=0.014),红细胞容量无显著影响。
  • 20W运动时动脉乳酸达格列净组为-0.70±0.77 mM,安慰剂组为0.37±1.29 mM(P=0.006),20W或峰值运动氧耗无差异。

临床怎么用

  • 达格列净可能通过降低静息和运动PCWP及血浆容量改善HFpEF患者血流动力学。

局限性

  • 单中心、样本量小(38例),结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sodium-glucose cotransporter-2 inhibitors reduce risk of hospitalization for heart failure in patients who have heart failure with preserved ejection fraction (HFpEF), but the hemodynamic mechanisms underlying these benefits remain unclear. This study sought to determine whether treatment with dapagliflozin affects pulmonary capillary wedge pressure (PCWP) at rest and during exercise in patients with HFpEF. METHODS: This was a single-center, double-blinded, randomized, placebo-controlled trial testing the effects of 10 mg of dapagliflozin once daily in patients with HFpEF. Patients with New York Heart Association class II or III heart failure, ejection fraction ≥50%, and elevated PCWP during exercise were recruited. Cardiac hemodynamics were measured at rest and during exercise using high-fidelity micromanometers at baseline and after 24 weeks of treatment. The primary end point was a change from baseline in rest and peak exercise PCWPs that incorporated both measurements, and was compared using a mixed-model likelihood ratio test. Key secondary end points included body weight and directly measured blood and plasma volumes. Expired gas analysis was performed evaluate oxygen transport in tandem with arterial lactate sampling. RESULTS: Among 38 patients completing baseline assessments (median age 68 years; 66% women; 71% obese), 37 completed the trial. Treatment with dapagliflozin resulted in reduction in the primary end point of change in PCWP at rest and during exercise at 24 weeks relative to treatment with placebo (likelihood ratio test for overall changes in PCWP; P<0.001), with lower PCWP at rest (estimated treatment difference [ETD], -3.5 mm Hg [95% CI, -6.6 to -0.4]; P=0.029) and maximal exercise (ETD, -5.7 mm Hg [95% CI, -10.8 to -0.7]; P=0.027). Body weight was reduced with dapagliflozin (ETD, -3.5 kg [95% CI, -5.9 to -1.1]; P=0.006), as was plasma volume (ETD, -285 mL [95% CI, -510 to -60]; P=0.014), but there was no significant effect on red blood cell volume. There were no differences in oxygen consumption at 20-W or peak exercise, but dapagliflozin decreased arterial lactate at 20 W (-0.70 ± 0.77 versus 0.37 ± 1.29 mM; P=0.006). CONCLUSIONS: In patients with HFpEF, treatment with dapagliflozin reduces resting and exercise PCWP, along with the favorable effects on plasma volume and body weight. These findings provide new insight into the hemodynamic mechanisms of benefit with sodium-glucose cotransporter-2 inhibitors in HFpEF. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT04730947.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Borlaug BA, Reddy YNV, Braun A, et al. Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial. Circulation. 2023. PMID: 37534453. doi:10.1161/CIRCULATIONAHA.123.065134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。